H.C. Wainwright assumed coverage of Terns Pharmaceuticals (TERN) with a Neutral rating and $7.44 price target The firm is cautiously optimistic on TERN-701 and TERN-601 as it awaits “differentiation data.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TERN:
- Terns Pharmaceuticals: A Promising Buy Amid Competitor Challenges in the Oral GLP-1 Space
- Disappointing competitor oral GLP-1 data an opportunity for Terns, says Mizuho
- Terns Pharmaceuticals Reports Q2 2025 Financial Results
- Terns Pharmaceuticals reports Q2 EPS (26c), consensus (29c)
- Terns Pharmaceuticals initiated with Early-Stage Biotech at Goldman Sachs